Oncolytics Biotech (TSE:ONC) Stock Passes Above 200-Day Moving Average – Here’s Why

Oncolytics Biotech Inc. (TSE:ONC)’s share price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of C$13.50 and traded as high as C$14.90. Oncolytics Biotech shares last traded at C$14.90, with a volume of 280 shares traded.

Oncolytics Biotech Stock Down 1.3%

The company has a 50-day moving average of C$14.90 and a 200-day moving average of C$13.50. The company has a current ratio of 2.99, a quick ratio of 8.86 and a debt-to-equity ratio of 11.75. The company has a market capitalization of C$1.50 billion, a price-to-earnings ratio of -40.27 and a beta of 0.80.

Insider Activity

In related news, Director Patricia Andrews bought 35,400 shares of the company’s stock in a transaction on Thursday, February 12th. The shares were bought at an average price of C$1.18 per share, with a total value of C$41,772.00. Following the transaction, the director owned 78,128 shares in the company, valued at approximately C$92,191.04. This trade represents a 82.85% increase in their ownership of the stock. Also, Director Bernd Robert Seizinger purchased 60,000 shares of the business’s stock in a transaction on Wednesday, February 11th. The shares were bought at an average price of C$1.14 per share, for a total transaction of C$68,400.00. Following the purchase, the director directly owned 526,991 shares in the company, valued at C$600,769.74. This represents a 12.85% increase in their position. Over the last quarter, insiders have acquired 289,232 shares of company stock valued at $335,760. 3.82% of the stock is owned by company insiders.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.